Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (GB:0HD2)
:0HD2
0HD2 Stock Chart & Stats
Day’s Range― - ―
52-Week Range$209.75 - $470.00
Previous CloseN/A
Volume1.06K
Average Volume (3M)1.04K
Market Cap
$58.53B
Enterprise Value$42.48B
Total Cash (Recent Filing)$2.86B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Oct 23, 2025EPS Estimate
0.23Last Dividend Ex-Date
Mar 15, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding131,079,010
10 Day Avg. Volume2,773
30 Day Avg. Volume1,044
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue17.25
Enterprise Value/Gross Profit20.63
Enterprise Value/Ebitda-248.52
Forecast
1Y Price Target
$432.64Price Target Upside-3.36% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering28
Bulls Say, Bears Say
Bulls Say
Market ExpansionALNY received regulatory approval in Brazil, Europe, the UK, and Japan for its therapies, expanding its market reach.
Product LaunchThe U.S. approval and launch of AMVUTTRA in ATTR-CM led to a sharp inflection in sales, prompting a $600M upward revision to full-year guidance.
Bears Say
Profit MarginsA 30% royalty payment to Sanofi affects Alnylam's margins, making Amvuttra less profitable.
Valuation ConcernsAlnylam's valuation is stretched, which still raises concerns despite positive market performance.
Alnylam Pharma News
0HD2 FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest share price was $209.75 and its highest was $470.00 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $58.53B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Oct 23, 2025 which is in 52 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Jul 31, 2025. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.544 by $0.034.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Overvalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Alnylam Pharmaceuticals dividends here
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 0.23.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 131,079,010 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.544. Following the earnings report the stock price went up 13.812%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0HD2
Alnylam Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$432.64 (-3.36% Downside)
$432.64 (-3.36% Downside)
Blogger Sentiment
Bullish
GB:0HD2 Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.57%
12-Months-Change
Fundamentals
Return on Equity
-257.82%
Trailing 12-Months
Asset Growth
13.88%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
0HD2 Company Deck
0HD2 Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Alnylam Q2 2025 highlighted strong commercial performance and successful product launches, particularly for AMVUTTRA in ATTR-CM, leading to an upgraded financial outlook. Despite some decreases in collaboration revenue and product sales margins, the overall sentiment remains highly positive due to the robust growth and positive future guidance.View all GB:0HD2 earnings summaries0HD2 Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
0HD2 Stock 12 Month Forecast
Average Price Target
$432.64
▼(-3.36% Downside)
Technical Analysis
Ownership Overview
0.42% Insiders
48.21%
Mutual Funds
0.31% Other Institutional Investors
35.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---